S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Brian Edward Miller, Executive Vice President and Chief Digital Officer at Intuitive Surgical Inc . (NASDAQ:ISRG), recently sold shares totaling approximately $6.37 million, according to a recent SEC filing. The transactions, executed on March 11 and 12, involved multiple sales of common stock at prices ranging from $482.824 to $512.06 per share. The timing is notable as InvestingPro data shows the stock has declined over 12% in the past week, with current trading at $497.30.
The filing also disclosed that Miller exercised stock options to acquire shares at prices between $177.9867 and $208.9, totaling approximately $1.11 million. These transactions were conducted under a pre-arranged trading plan that complies with SEC Rule 10b5-1, which allows company insiders to set up a predetermined plan for selling stocks to avoid insider trading accusations. The company currently trades at a P/E ratio of 76.36, reflecting its premium valuation in the medical devices sector.
Following these transactions, Miller’s direct ownership stands at 5,758 shares. Despite recent market volatility, Intuitive Surgical maintains strong fundamentals with a current ratio of 4.07 and minimal debt levels. InvestingPro subscribers can access 16 additional investment tips and a comprehensive analysis of ISRG’s financial health, which is currently rated as "GOOD" by our proprietary scoring system.
In other recent news, Intuitive Surgical has reported a strong finish to 2024, with its fourth-quarter earnings and revenue surpassing expectations. The company achieved a 10% revenue beat and a 24% earnings per share (EPS) beat, as noted by RBC Capital Markets, which maintained an Outperform rating with a $641 price target. Piper Sandler also increased its price target to $670, citing Intuitive Surgical’s impressive performance and optimistic outlook for 2025, including a projected 13-16% increase in procedure volume. Meanwhile, Bernstein has set a $700 price target, highlighting a 38% year-over-year increase in EPS to $2.21 for the fourth quarter, surpassing consensus estimates by 22%.
Despite these positive earnings reports, Oppenheimer maintained a Perform rating, expressing caution due to concerns about market saturation in the U.S. and the pricing of the new da Vinci (EPA:SGEF) 5 (dV5) system. Truist Securities, however, raised its price target to $666, maintaining a Buy rating and emphasizing the potential for continued growth with the mid-year launch of the dV5 system. Intuitive Surgical’s gross margin guidance for 2025 was slightly below some analyst expectations, but firms like Piper Sandler anticipate a return to over 70% gross margins in the mid-term. The upcoming launch of the dV5 system and new distribution agreements in Europe are seen as pivotal developments for the company’s growth strategy.
Overall, Intuitive Surgical’s recent earnings and strategic plans have led to a range of positive analyst ratings and increased price targets, reflecting confidence in the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.